Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) gapped down before the market opened on Friday following a dissappointing earnings announcement. The stock had previously closed at $17.68, but opened at $15.47. Daiichi Sankyo shares last traded at $16.50, with a volume of 633 shares.
The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02). Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold”.
Daiichi Sankyo Stock Down 11.7%
The stock’s fifty day moving average price is $16.52 and its 200 day moving average price is $17.74. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. The stock has a market cap of $29.99 billion, a P/E ratio of 17.13, a price-to-earnings-growth ratio of 3.10 and a beta of -0.17.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
See Also
- Five stocks we like better than Daiichi Sankyo
- Generac’s AI Power Story Is Becoming Bigger Than the Weather
- Everyone’s Focused on China—But That’s Not ASML’s Biggest Risk
- Chipotle Mexican Grill Stock Rallies as Q2 Results Top Fears, Guidance Rises
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
